The COVID-19 pandemic has led to a global effort to develop and distribute vaccines. However, access to these vaccines has been uneven, with wealthier nations being able to secure early supplies while many developing nations are still waiting for their first shipments.
Existing Problems
This disparity has been driven in part by the fact that most vaccine manufacturers are based in wealthier countries, and that these countries have been able to pre-order large quantities of vaccines. There is a growing recognition that this inequitable distribution of vaccines is not sustainable in the long term and that all countries need to be vaccinated in order to truly end the pandemic.
However, there are significant challenges in getting vaccines to people in developing nations. Many people in developing nations are skeptical of vaccines, due to a lack of trust in government and health authorities. There is also a fear that receiving a vaccine could lead to other health problems, or that the vaccine may not work.
Having witnessed this COVID pandemic, we still don’t know how can we survive in the next possible widespread health concern. That’s where Bioviratech has gone ahead to propose a solution that can solve people’s access to the vaccines regardless of the country’s status or governmental selfishness.
Innovative Solution
Bioviratech is basically a legal obligation, a promise by a pharmaceutical company to embrace a more even distribution of vaccines. It circumvents government and regulatory limitations of international distribution by a simple collaboration or subsidiary transaction across geographical regions i.e. Pfizer (USA) BioNTech (Germany).
Bioviratech delivers an option to purchase a vaccine, in the next pandemic. This doesn’t include the cost of the vaccine. It basically leverages blockchain technology as it is truly decentralized by nature and offers inexpensive transactions.
This could only be affordable if, the legal contracts are created at scale. And the unique factor of each legal contract is, the unique smart contract number. It is more like a standard insurance contract and the uniqueness being the consumer’s details and reference number.
In order to offer a tokenized solution, Bioviratech is conducting a discounted and controlled BVT presale between 1st and 31st of August. On the other hand, the public sale will be conducted through ICO during the month of November. There will be an incremental cap during ICO as the day passes until the soft cap has reached.
BVT purchasers receive token smart contracts that entitle them to a vaccine from the primary distribution. These can be redeemed during a future pandemic and/or the excess sold at a price the buyer is willing to pay. The cost of the vaccine is not included. ICO funds will be directly deposited into an escrow account of your choice and refunded if the protocol is not completed.
Once all three stages of the ICO have been completed, purchasers will have the option to trade on exchanges, via OTC (over the counter) or directly between parties. There is supposed to be a rise in the value of the token / smart contracts during these trades and early investors will be benefitted accordingly.
Website: https://www.bioviratech.com/
Whitepaper: https://www.bioviratech.com/wp-content/uploads/2022/07/Bioviratech-1.pdf